Lu Jing-Shun, Song Chen-Yu, Cheng Wen-Jing, Wang Kai-Yang
Department of Orthopedics, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
World J Stem Cells. 2025 Apr 26;17(4):102923. doi: 10.4252/wjsc.v17.i4.102923.
In this editorial, we comment on the recent article by Xiao focusing on their investigation into whether the therapeutic efficacy of serum-free human umbilical cord mesenchymal stem cells (MSCs) differs from that of serum-containing human umbilical cord MSCs in a mouse model of knee osteoarthritis (OA). The incidence of OA has significantly increased in recent years, primarily owing to sports-related injuries or degenerative diseases. However, the regenerative capacity of articular cartilage remains limited, necessitating artificial joint replacement for patients with advanced OA to enhance the quality of life. MSCs have been widely used in the clinical treatment of OA owing to their multidirectional differentiation potential and immunomodulatory effects. The focus of this paper lies in elucidating the mechanism underlying MSC transplantation for the treatment of knee OA, while also addressing the challenges encountered in MSC therapy and outlining future directions.
在这篇社论中,我们对肖等人最近的文章进行评论,该文章聚焦于他们在膝骨关节炎(OA)小鼠模型中对无血清人脐带间充质干细胞(MSCs)与含血清人脐带MSCs的治疗效果是否存在差异的研究。近年来,OA的发病率显著上升,主要归因于运动相关损伤或退行性疾病。然而,关节软骨的再生能力仍然有限,对于晚期OA患者需要进行人工关节置换以提高生活质量。由于MSCs具有多向分化潜能和免疫调节作用,它们已被广泛应用于OA的临床治疗。本文的重点在于阐明MSCs移植治疗膝OA的潜在机制,同时也探讨MSCs治疗中遇到的挑战并概述未来方向。